Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan + pembrolizumab in first-line PD-L1+ triple-negative breast cancer
NCT05382286Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Gilead Sciences. Started Jul 2022; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05382286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382286.